Adherence Intervention in Patients With Metastatic Breast Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
To evaluate the preliminary efficacy of a multicomponent adherence intervention focused on enhancing digital equity and pharmaco-equity among nonadherent patients with metastatic breast cancer (MBC) and cardiovascular disease (CVD) risk factors on endocrine therapy (ET), CDK4/6 inhibitor (CDK 4/6i), and CVD medications. To assess the acceptability and appropriateness of this intervention in patients with MBC and CVD risk factors through validated measures of implementation outcomes. To gain a deeper understanding of the impact of social determinants of health (SDOH) on medication nonadherence through semi-structured interviews with a subset of study participants.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek powyżej 18 lat
- •Rozpoznany rak piersi w stadium zaawansowanym (przerzuty) - leczony hormonalnie i inhibitorami CDK4/6
- •Przepisane leki na wysokie ciśnienie lub cholesterol
- •Potwierdzony brak regularnego przyjmowania leków onkologicznych lub kardiologicznych
✗ Disqualifies
- •Nieznajomość języka angielskiego lub hiszpańskiego
- •Problemy z pamięcią lub myśleniem uniemożliwiające udział w badaniu
- •Poważne zaburzenia psychiczne lub uzależnienia
- •Niemożliwość uczestnictwa przez 28 tygodni
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 99 Years
- Last updated (source)
- July 28, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Columbia University Medical Center
New York, United States
Trial contact
Research Nurse Navigator
Claire Sathe, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/29/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.